Last edition
News about
New patient-derived xenograft study demonstrates strong synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, paving the way for expanded clinical evaluation in Phase 1/2a trials.
EMA Fast-Tracks Review of New Metastatic Pancreatic Cancer Drug
The European Medicines Agency (EMA) has initiated a phased review of a new medicine for metastatic pancreatic cancer, accelerating its assessment to address a significant unmet medical need.
Sino Biopharma and AstraZeneca Sign Licensing Deal for TQC3721
Sino Biopharmaceutical has signed an exclusive licensing agreement with AstraZeneca to develop, manufacture, and commercialise TQC3721, a novel PDE3/4 inhibitor for respiratory diseases.
Jascayd (Nerandomilast) Wins UK MHRA Approval for Pulmonary Fibrosis Treatment
Nerandomilast (Jascayd) has been approved for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), expanding treatment options for these chronic lung diseases.
Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili
Biocon has published pivotal clinical data supporting the effectiveness of Yesafili, its Food and Drug Administration (FDA)-approved interchangeable aflibercept biosimilar, demonstrating comparable safety, efficacy, and immunogenicity.
Government Notifies Navi Mumbai Airport as Port for Import of Drugs under Drugs Rules, 1945
The Government of India has notified Navi Mumbai Airport as a port for drug imports under the Drugs Rules, 1945, expanding notified entry points to 42 and strengthening pharmaceutical logistics.
Evogene and Tel Aviv University Launch AI Drug Discovery Initiative
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery have launched a joint initiative combining Artificial Intelligence (AI)-driven computational chemistry with advanced experimental capabilities to accelerate small-molecule drug discovery.
Insilico Medicine Advances AI-Discovered IPF Drug Rentosertib into Phase III Clinical Trial
Rentosertib, formerly known as ISM001-055/INS018_055, is a potentially first-in-class oral small-molecule inhibitor targeting TNIK (TRAF2 and NCK-interacting kinase) for the treatment of IPF, a progressive and irreversible lung disease with limited treatment options.
Vertex to Acquire Crinetics Pharmaceuticals for USD 10 Billion
Under the terms of the agreement, Vertex will acquire all outstanding shares of Crinetics for USD 85 per share in cash, representing a net transaction value of approximately USD 8.8 billion after accounting for estimated cash acquired.
UK MHRA Approves Retifanlimab for Merkel Cell Skin Cancer
The UK MHRA has approved retifanlimab (ZYNYZ) for the treatment of advanced Merkel Cell Carcinoma (MCC), a rare and aggressive skin cancer with significant unmet medical need.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy